Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR – Free Report) – Investment analysts at HC Wainwright lowered their FY2027 earnings per share (EPS) estimates for Pharming Group in a research report issued to clients and investors on Monday, September 14th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn $0.50 per share for the year, down from their prior estimate of $0.60. HC Wainwright has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for Pharming Group’s current full-year earnings is $0.22 per share.
A number of other equities analysts have also recently commented on the company. Canaccord Genuity Group increased their target price on Pharming Group from $37.00 to $38.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Zacks Research downgraded Pharming Group from a “hold” rating to a “strong sell” rating in a research note on Friday, July 31st. Weiss Ratings restated a “sell (d)” rating on shares of Pharming Group in a report on Friday, August 7th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Pharming Group in a research note on Thursday, July 30th. Three research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $38.67.
Pharming Group Stock Down 2.5%
PHAR opened at $10.55 on Wednesday. The company has a market cap of $746.73 million, a PE ratio of 87.92 and a beta of 0.01. Pharming Group has a twelve month low of $9.62 and a twelve month high of $21.34. The company has a 50-day moving average price of $11.92 and a 200 day moving average price of $13.75. The company has a quick ratio of 2.31, a current ratio of 3.01 and a debt-to-equity ratio of 0.34.
Pharming Group (NASDAQ:PHAR – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%.
About Pharming Group
Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing and commercializing treatments for rare diseases. The company uses its expertise in protein replacement therapies and other biotechnology platforms to address conditions with limited treatment options.
Pharming’s principal product is Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause severe swelling.
Further Reading
- Five stocks we like better than Pharming Group
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
